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Evidence suggests a proinflammatory role of lyso-
phosphatidic acid (LPA) in various pathologic abnor-
malities, including in the central nervous system.
Herein, we describe LPA as an important mediator of
inflammation after spinal cord injury (SCI) in ze-
brafish and mice. Furthermore, we describe a novel
monoclonal blocking antibody raised against LPA that
potently inhibits LPA’s effect in vitro and in vivo. This
antibody, B3, specifically binds LPA, prevents it from
interacting with its complement of receptors, and
blocks LPA’s effects on the neuronal differentiation of
human neural stem/progenitor cells, demonstrating
its specificity toward LPA signaling. When adminis-
tered systemically to mice subjected to SCI, B3 substan-
tially reduced glial inflammation and neuronal death.
B3-treated animals demonstrated significantly more
neuronal survival upstreamof the lesion site, with some
functional improvement. This study describes the use of
anti-LPA monoclonal antibody as a novel therapeutic
approach for the treatment of SCI. (Am J Pathol 2012,
181:978–992; http://dx.doi.org/10.1016/j.ajpath.2012.06.007)
Spinal cord injury (SCI) often results in permanent damage
at the site of the injury from the initial neurotrauma, and it is
complicated by inflammatory and other processes that pre-
vent neuronal regeneration and recovery by the central
nervous system (CNS). Many approaches are under way to
investigate mechanisms for improving neural regeneration
and promoting functional recovery, including blockage of
978axonal growth inhibitory molecules, treatment with growth-
promoting molecules, application of measures to reduce
glial scarring, and the development of methods to limit dif-
fuse inflammation and cell death. Thus, the key to an effec-
tive therapy after SCI is to identify factors that contribute to
acute and secondary events that limit regeneration and
functional recovery. Herein, we describe for the first time the
role of lysophosphatidic acid (LPA) as a significant contrib-
utor to acute and secondary injury processes, and we de-
scribe a novel therapeutic antibody against LPA that may
be useful as a treatment for SCI.
LPA is a bioactive lysophospholipid that is a collection
of structural analogs with a single functional glycerol al-
cohol phosphate moiety esterified to a variety of fatty acyl
hydrocarbons of varied lengths and degrees of satura-
tion. LPA is detected in various body fluids, including
serum and cerebrospinal fluid, and it is thought that LPA
is an inflammatory and wound-healing mediator, released
from activated platelets, astrocytes, and other cells par-
ticipating in the inflammatory process.1 LPA is also
known to induce the release of various proinflammatory
cytokines from a variety of cells, including astrocytes.2
LPA mainly acts through binding to its specific
G-protein–coupled receptors encoded by different
genes: LPA1/Edg-2/rec.1.3/vzg-1/Gpcr26/Mrec1.3, LPA 2/
Edg-4, LPA 3/Edg-7/RP4-678I3/HOFNH30, LPA4/P2Y9/
GPR23, LPA5/GPR92, LPA 6/P2Y5, GPR87, and P2Y10.
1 In
the developing nervous system, LPA targets most cell
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establishing the cerebral cortex.1,3 In the adult mamma-
lian nervous system, LPA1 is found in oligodendrocytes
and Schwann cells,4–8 whereas LPA2-5 are weakly ex-
pressed.8–11 LPA and its producing enzyme autotaxin
are present in the cerebrospinal fluid 12 and in the adult
brain, including in the white matter, choroid plexus, and
leptomeningeal cells.13–16 Furthermore, LPA can induce
astrocyte reactivity in the mouse brain17 and neuropathic
pain and demyelination in the spinal cord.18–20 Moreover,
various studies showed that LPA can stimulate astrocytic
proliferation,21 promote neuronal death,22 and mediate
microglial activation23 and is cytotoxic to the neuromicro-
vascular endothelium.24 Considering the pleiotropic ef-
fects of LPA on many key CNS cell types, together with
data showing localized up-regulation of LPA receptors
after injury in mice and humans,8,25 it is likely that LPA
regulates essential aspects of the cellular reorganization
after neural trauma, such as reactive astrogliosis and
neural degeneration. Thus, it is probable that LPA is a key
player in regulating response to injury and, consequently,
in modulating the outcome of CNS damage.
We used two animal models to examine the role of LPA
in an established regenerative (zebrafish) SCI injury
model and a nonregenerative (murine) model of SCI. We
first examined the role of LPA in a zebrafish spinal cord
transection model. This in vivo model regenerates dam-
aged nerves and recovers full locomotor ability after SCI
in a remarkably short period after injury.26,27 We then
assessed the effect of LPA on inflammatory, glial, and
neuronal cell activity and on neuronal regeneration in the
zebrafish proregenerative model. Second, we used a well-
characterized murine model of SCI to evaluate the role of
LPA in a nonregenerative system. For this evaluation, we
developed a novel and specific mouse monoclonal anti-
body (mAb) against LPA that blocks LPA’s effects in vitro on
neural stem/progenitor cells (NS/PCs) and in vivo by dem-
onstrating neuroprotection and improving the functional out-
comes of SCI in this murine model of SCI. Furthermore, we
show the mechanism of LPA’s effects in the CNS after SCI
by assessing its effect on the various CNS cell types. Thus,
using a regenerative model and a nonregenerative model,
we demonstrated the proinflammatory role of LPA during
SCI. This work highlights the importance of LPA modulation
in neurotrauma and provides proof of concept for the block-
age of LPA signaling to treat SCI. This work demonstrates
that the anti-LPA mAb may be a useful therapeutic reagent
for the treatment of SCI.
Materials and Methods
Ethics
All the experiments were approved by the human or
animal research ethics committees of the University of
Melbourne, St. Vincent’s Hospital, and Monash University
in accordance with the requirements of the National
Health and Medical Research Council of Australia (Aus-
tralian Code of Practice for the Care and Use of Animalsfor Scientific Purposes and the National Statement on
Ethical Conduct in Human Research).
Reagents
Dilutions of LPA (Sigma-Aldrich, Castle Hill, Australia)
were made in 0.1% fatty acid–free bovine serum albumin
(BSA; final concentration, 0.01% BSA; Sigma-Aldrich).
The murine anti-LPA mAb B3 and the isotype-matched
control IgGB2 mAb were obtained from Lpath Inc. (San
Diego, CA).
Zebrafish Strains
Two transgenic (Tg) lines were used: macrophage-ex-
pressed gene1 Tg(mpeg1:GFP) and neutrophils Tg(mpx:
GFP)i114,3,28,29 GFAP promoter Tg(GFAP:GFP)mi200130 or
motor neuron Islet1 promoter Tg(isl1:GFP)2rw012.31
Spinal Cord Lesion
Spinal cords of zebrafish were lesioned as described
elsewhere.27,32 Briefly, adult fish (3 to 6 months old) were
anesthetized in 0.033% tricaine methanesulfonate (MS-
222) in fish tank water until respiratory movements of the
opercula stopped (3 to 5 minutes). A longitudinal incision
was made halfway between the dorsal fin and the oper-
culum, corresponding to the eighth vertebra (5 mm
caudal to the operculum) of the spinal cord. The initial
incision was made through the muscle layer, and the
vertebral column was exposed by holding the muscle
tissue aside. Then, the vertebral column was completely
transected using microscissors. A single injection of 10
L of 5 mol/L LPA in 0.1% BSA or 0.1% BSA alone
(controls) was performed into the lesion site and around
the muscle tissue immediately after spinal cord transec-
tion. The wound was sealed with a drop of 3M Vetbond
tissue adhesive (3M, St. Paul, MN). The gills of the fish
were flushed in a tank of fresh fish water by gently pulling
the fish through the water. Fish resumed breathing within
a few seconds.
Bromodeoxyuridine Application
Injections of 50 L of i.p. bromodeoxyuridine (BrdU) (2.5
mg/mL; Sigma-Aldrich) were performed 0, 2, and 4 days
after lesioning.
Locomotor Analysis
A scale from 1 to 5 was designed to assess fish motor
function improvement at different time points after spinal
cord transection as described previously.32
Zebrafish Tissue Preparation
To collect tissue after SCI, fish were deeply anesthetized
with an overdose of 0.033% tricaine methanesulfonate
(MS-222). The spinal cords were exposed and fixed for 2
hours in 4% paraformaldehyde (PFA) in PBS at room
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to 3 hours at room temperature, followed by immersion in
30% sucrose in PBS overnight at 4°C before embedding
in OCT. Spinal cords were cryostat sectioned at 20 m
thickness. Analyses were performed in each Tg strain at
different time points after SCI (as indicated in Results).
Time points were specifically chosen to be the most ap-
propriate for each aspect investigated based on prelim-
inary data not shown.
TUNEL Method
TUNEL staining was performed on the mpx:GFP:EGFP
line 6 hours after SCI using an in situ cell death detection
kit, TMR red (Roche Diagnostics GmbH, Mannheim, Ger-
many), according to the manufacturer’s protocol.
Immunohistochemical Analysis
Sections were labeled using standard immunohisto-
chemical procedures to determine the expression and
localization of BrdU. Sections were postfixed for 10 min-
utes in 4% PFA, and antigen retrieval was performed by
incubating the sections for 15 minutes in 2 mol/L HCl,
followed by blocking (PBS-TX containing 5% normal goat
serum; Invitrogen, Carlsbad, CA) for 1 hour at room tem-
perature. Mouse anti-BrdU (1:400; Roche Diagnostics) in
blocking solution was incubated overnight at 4°C. After
washing, sections were incubated for 2 hours at room
temperature, with secondary antibodies diluted in block-
ing solution [goat anti-mouse Alexa Fluor 594 (1:1000;
Molecular Probes Inc., Eugene, OR)].
RT-PCR of Spinal Cord Tissue
Approximately 0.5 g of brain, muscle, liver, and spinal cord
tissues each were dissected from wild-type zebrafish, and
RNA was extracted using TRI reagent (Sigma-Aldrich). To-
tal RNA was reversed transcribed using the SuperScript III
Reverse Transcriptase kit (Invitrogen), and the products
were analyzed by RT-PCR. PCR products were amplified
for 31 cycles and were separated on 2% agarose gel.
-Actin expression was evaluated as an internal control. The
primer sequences used were LPAR133 and -actin (for-
ward: 5=-GCATTGCTGACCGTATGCAG-3=; reverse: 5=-
GATCCACATCTGCTGGAAGGTGG-3=).
Probe Generation and in Situ Hybridization
A 1208-bp fragment of LPAR1 was amplified from mRNA
templates with Platinum Taq DNA polymerase (Invitro-
gen) and was cloned into pGEM-T easy vector system
(Promega Corp., Madison, WI). Primers used were as
previously described.33 Plasmids were linearized, tran-
scribed, and labeled using SP6 polymerase (Roche Di-
agnostics) and a DIG RNA labeling mix (Roche Diagnos-
tics). In situ hybridization was performed by standard
procedures on 30-m sections. After staining, tissues
were imaged using an Axio Imager Z1 compound micro-
scope (Carl Zeiss MicroImaging GmbH, Jena, Germany).Specificity of the Anti-LPA Antibody B3
The specificity of the murine anti-LPA IgG2 mAb B3 was
determined by competition enzyme-linked immunosor-
bent assay (ELISA) using methods similar to those pub-
lished for antibodies directed against sphingosine-1-
phosphate.34 The 18:0 LPA coating material was diluted
to 0.33 g/mL in carbonate buffer (100 mmol/L NaHCO3,
33.6 mmol/L Na2CO3, pH 9.5). Plates were first coated
with 100 L per well of this coating solution and were
incubated at 37°C for 1 hour. The plates were then
washed four times with PBS (100 mmol/L Na2HPO4, 20
mmol/L KH2PO4, 27 mmol/L KCl, 1.37 mmol/L NaCl, pH
7.4) and were blocked with 150 L per well PBS  1%
BSA  0.1% Tween 20 for 1 hour at room temperature.
The murine B3 IgG2 mAb was tested against lipids that
are structurally and chemically similar to LPA at 5, 2.5,
1.25, 0.625, and 0.0 mol/L. (Data in Table 1 are given for
the 2.5-mol/L level of competitive lipid and are ex-
pressed as a percentage of inhibition of binding). The
antibody was diluted to 0.5 g/mL in PBS  0.1% Tween
20 and was combined with the lipid samples at a 1:3 ratio
of antibody to sample on a nonbinding plate (usually 100
L of mAb and 300 L of samples/standards, enough to
run in triplicate). The plates were then washed four times
with PBS and were incubated for 1 hour at room temper-
ature with 100 L per well of the primary antibody com-
bined with the samples. Next, the plates were washed
four times with PBS and then were incubated for 1 hour at
room temperature with 100 L per well of horseradish
peroxidase–conjugated goat anti-mouse antibody di-
luted 1:20,000 in PBS  1% BSA  0.1% Tween 20.
Again, the plates were washed four times with PBS and
were developed using 100 L per well of 3,3=,5,5=-tetram-
ethylbenzidine substrate at 4°C. After 8 minutes, the re-
action was stopped with 1 mol/L H2SO4, 100 L per well.
The OD was measured at 450 nm using a Thermo Multi-
skan EX microplate photometer (Thermo Scientific, Rock-
ford, IL). Raw data were transferred to GraphPad soft-
ware version 5 (GraphPad Software Inc., San Diego, CA)
for analysis. Values for percentage inhibition were calcu-
lated for each lipid using a Microsoft Excel spreadsheet
(Microsoft Corp., Redmond, WA).
LPA Receptor Signaling Assay
The ability of the murine anti-LPA antibody B3 to block
LPA signaling via its receptor was studied in a series of
assays using cells supplied by DiscoveRx (Freemont,
CA). For the present studies, the DiscoveRx PathHunter
CHO-K1 EDG2 or EDG4 or EDG7 -arrestin cell lines
were used to test LPA signaling to cells overexpressing
these LPA receptors. DiscoverRX uses enzyme fragment
complementation technology in which two weakly com-
plementing fragments of the -galactosidase enzyme are
expressed in stable transfected cells. In this system, one
fragment of the -galactosidase, termed the enzyme ac-
ceptor, is fused to the C-terminus of the -arrestin2. The
complementing fragment of -galactosidase, termed the
ProLink tag (DiscoveRx), is expressed as a fusion protein
with LPA1-3 at the C-terminus. On activation, the LPA
-erythro
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-arrestin. The interaction of -arrestin and the LPA re-
ceptor forces the interaction of ProLink and enzyme ac-
ceptor, thus allowing complementation of the two frag-
ments of -galactosidase and the formation of functional
enzyme capable of hydrolyzing substrate and generating
a chemiluminescent signal. Complementation is driven
by protein-protein interaction between arrestin–enzyme
acceptor and ProLink-labeled LPA receptor. Cells were
grown in culture following the vendor recommendations,
and assays were run in a 96-well plate format. Assay
plates were prepared by collecting cells in a sterile
50-mL conical tube using 5 mL of Cellstripper nonenzy-
matic cell dissociation buffer (Mediatech Inc., Oakland,
CA). Cells were spun at 1100 rpm for 5 minutes, super-
natant was removed, and cell pellet was resuspended in
5 mL of complete media with antibiotics. The cells were
then counted using an automated cell counter and were
plated at 20,000 cells per well (100 L of total volume in
each well) in 96-well white clear-bottom plates. Plates
were incubated at 37°C in a humidified 5% CO2 atmo-
sphere. After 24 hours, cells were starved in reduced
serum media and incubated at 37°C for 24 hours. For the
LPA binding experiments, a 100 mol/L stock of 18:2 LPA
(Avanti Polar Lipids, Alabaster, AL) was diluted 0 to 10
mmol/L in media containing 1 mg/mL of BSA, and for the
antibody inhibition experiment, 200 nmol/L LPA for LPA1
receptor or 400 nmol/L LPA for LPA2 and 3-overexpresing
cells was incubated with 0 to 2000 mg/mL anti-LPA anti-
body. The media from the 96-well plates containing the
Table 1. Competition ELISA
Competitive lipid 2.5 mol/L
1-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphate (1-linole
D-erythro-sphingosine-1-phosphate (S1P)
D-erythro-sphingosine (SPH)
D-erythro-sphingosine phosphocholine (lyso sphingomyelin, S
1-Stearoyl-2-hydroxy-sn-glycerol-3-phosphocholine (LPC)
1-Stearoyl-2-hydroxy-sn-glycerol-3-phosphoethanolamine (LP
1-Stearoyl-2-hydroxy-sn-glycero-3-[phosho-rac-1-glycerol)] (L
1-Oleoyl-2-hydroxy-sn-glycerol-3-phospho-L-serine (LPS)
1-Olyoyl-2-Hydroxy-sn-glycero-3-phosphoinositol (LPI)
1,2-Dipalmitoyl-sn-glycero-3-[phospho-L-serine] (DPPS)
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC)
1,2-Dilinoleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (18:2
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphate (16:0–18:1) (PA)
1,2-Dieladoyl-sn-glycero-3-phosphoethanolamine
1,2-Diundecanoyl-sn-glycero-3-phosphocholine
1-Alkyl-2-acetoyl-sn-glycero-3-phosphocholine (PAF)
1-Oleoyl-sn-glycero-2-3-cyclic-phosphate (cyclic LPA)
1-Alkyl-2-hydroxy-sn-glycero-3-phosphocholine (Lyso PAF)
1-Bromo-3(S)-hydroxy-4- (palmitoyloxy) butyl] phosphonate (
1,2-Dioleoyl-sn-glycerol (DAG)
(R,R)2,2=-bisdodecyl-LBPA
2-Arachidonoyl glycerol (2-AG)
Glycerol phosphate
2-AG, 2-arachidonoyl glycerol; 18;2 PG, 1,2-Dilinoleoyl-sn-Glycero-
butyl] phosphonate; Cyclic LPA, 1-Oleoyl-sn-Glycero-2-3-Cyclic-Phospha
L-Serine]; Lyso PAF, 1-Alkyl-2-Hydroxy-sn-Glycero-3-Phosphocholine; L
droxy-sn-Glycerol-3-Phosphoethanolamine; LPG, 1-Stearoyl-2-Hydroxy-sn
phoinositol; LPS, 1-Oleoyl-2-hydroxy-sn-glycerol-3-phospho-L-serine; PA
PAF, 1-Alkyl-2-Acetoyl-sn-Glycero-3-Phosphocholine; PC, 1,2-diundecano
lamine; POPC, 1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine; S1P, D
SPH, D-erythro-Sphingosine.cells were removed, and 90 L of either LPA or LPA plusanti-LPA mAb was added to each well. The plates were
incubated at 37°C in a humidified 5% CO2 atmosphere
for 90 minutes. Plates were then washed with 300 L of
media, and 100 L of new media plus 50 L of freshly
made working detection reagent solution (DiscoverRx)
was added to each well. The plates were incubated in the
dark at room temperature for an additional 90 minutes.
Finally, the plates were read on a standard luminescence
plate reader. Data were fit to a four-parameter equation
(GraphPad Prism; GraphPad Software) and were ana-
lyzed using GraphPad Prism 5 software. The standard
relative light units were graphed using a four-parameter
fit equation.
Neural Induction of Human Embryonic Stem
Cells into NS/PCs
The human embryonic stem cell lines HES-3 (WiCell,
Madison, WI) and ENVY (ES Cell International, Singa-
pore) were used in this study. For each type of experi-
ment, medium was changed every second day. Neural
induction by noggin (500 ng/mL; R&D Systems, Minne-
apolis, MN) was performed as described.35 Noggin-
treated cells were harvested after 14 days and were
further subcultured as NS/PCs in suspension in neural
basal medium together with basic fibroblast growth factor
and epidermal growth factor (20 ng/mL each) as neuro-
spheres.36 In the neurosphere formation assay, neuro-
spheres were grown in the presence of various treat-
B3 inhibition (%)
, 18:2 LPA) 71
4
3
2
2
2
8
2
3
3
1
0
0
6
1
4
16
6
A) 6
5
2
7
3
pho-rac-(1-glycerol)]; BrP LPA, 1-Bromo-3(S)-hydroxy-4- (palmitoyloxy)
, 1,2-dioleoyl-sn-glycerol; DPPS, 1,2-Dipalmitoyl-sn-Glycero-3-[Phospho-
tearoyl-2-Hydroxy-sn-Glycerol-3-Phosphocholine; LPE, 1-Stearoyl-2-Hy-
o-3-[Phosho-rac-1-glycerol]; LPI, 1-Olyoyl-2-Hydroxy-sn-Glycero-3-Phos-
itoyl-2-Oleoyl-sn-Glycero-3-Phosphate (16:0-18:1) (phosphatidic acid);
ycero-3-phosphocholine; PE, 1,2-dieladoyl-sn-glycero-3-phosphoethano-
-Sphingosine-1-Phosphate; SPC, D-erythro-Sphingosine Phosphocholine;oyl LPA
PC)
E)
PG)
PG)
BrP-LP
3-[Phos
te; DAG
PC, 1-S
-Glycer
, 1-Palm
yl-sn-glments for 5 to 7 days, and the number of neurospheres
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tion assay, after 2 weeks of growth in suspension culture,
the neurospheres were plated as described onto laminin-
coated 8-well glass chamber slides (BD Falcon; BD Bio-
sciences, San Jose, CA) in neural basal medium lacking
growth factors,36 were allowed to attach, and were incu-
bated in the presence or absence of specified treatments
for 3 to 5 days. Cells were then fixed with 4% PFA for 10
minutes, blocked in 10% fetal calf serum–PBS  Tween
20, and immunostained with a mouse anti--tubulin
antibody (1:1000; Millipore, Billerica, MA) and its appro-
priate conjugated secondary antibodies (Alexa Fluor 568
or 488, 1:1000; Molecular Probes-Invitrogen). The spec-
ificity of the staining was verified by the absence of stain-
ing in the negative control immunoglobulin fraction
(Dako, Carpinteria, CA; data not shown). Frequency of
neuron-forming spheres was measured by counting the
number of spheres that showed neurons recognized by
-tubulin staining.
Spinal Cord Lesions in Mice
Animal experiments were performed using adult male
C57BL/6 mice. Mice were given a complete left hemisec-
tion at thoracic level T12, as previously described.37 To
address the bias, reproducibility, and robustness of this
study,38 we kept the injury homogenous and reproduc-
ible by excluding animals in which the spinal section was
invading the contralateral side and in which weakness
was observed in the right hind limb. This exclusion was
performed blindly at the end of the first week in an unbi-
ased and encoded manner. Approximately the same
numbers of animals were discarded from different groups
(isotype control versus treatment, 15% to 20%). Fur-
thermore, at all times, the investigator was blinded to the
nature of the drugs to be delivered. Decoding of the
samples was performed only once data were quantified
and analyzed.
The anti-LPA mAb,B3 or its IgG2 isotype-treated con-
trol (0.5 mg per mouse, 25 mg/kg) were encoded and
randomly delivered subcutaneously 30 minutes after le-
sioning and then twice weekly for a maximum of 2 weeks.
For short-term experiments, after 7 or 14 days, the ani-
mals were sacrificed and perfused with PBS, followed by
4% PFA; the spinal cords were removed, postfixed for 1
hour in 4% PFA, and then cryopreserved in 20% sucrose
overnight at 4°C for frozen sections. Control tissues were
taken from uninjured mice (sham).
For nerve regeneration and functional recovery, ani-
mals were injected for 2 weeks and were analyzed for up
to 5 weeks.37,39 Tetramethylrhodamine dextran was used
as an anterograde tracer to examine the extent of regen-
eration of lesioned lateral white matter tract axons or
corticospinal tract axons. Tracing was performed 1 week
before tissue collection. For lateral white matter tract ax-
ons, the mice were anesthetized and the spinal cord was
exposed in the cervical region as described previously
herein. The tracer was injected into the spinal cord at the
level of the cervical enlargement, ipsilateral to the lesion
(three injection points, 0.3 mL at 50 mg/mL each).37Immunohistochemical Analysis in Murine Tissue
Tissue was cut into 20-m sections using a cryostat and
was processed for immunohistochemical analysis as de-
scribed previously herein for zebrafish tissue. The pri-
mary antibodies used were mouse anti-NeuN (1:1000;
Millipore), rabbit anti–glial fibrillary acidic protein (GFAP)
(1:1000, Dako), mouse anti-GFAP (1:1000; Invitrogen),
mouse anti–chondroitin sulfate proteoglycan (1:200;
Sigma-Aldrich), rabbit anti–mitogen-activated protein ki-
nase (MAPK) (1:1000; Cell Signaling Technology Inc.,
Beverly, MA), rabbit anti–Ki-67 (1:200; Thermo), rabbit
antiactivated caspase-3 (1:200; BD Bioscience), and
mouse antisynaptophysin (1:1000; Chemicon, Temecula,
CA). The specificity of the staining was verified by the
absence of staining in negative controls consisting of the
appropriate negative control immunoglobulin fraction
(data not shown).
Cell apoptosis was performed using a TUNEL kit as
described previously herein for the zebrafish. DAPI was
used to visualize cell nuclei (Sigma-Aldrich). The speci-
ficity of the staining was verified by the absence of stain-
ing in negative controls without the TdT enzyme. Appro-
priate conjugated secondary antibodies (Alexa Fluor 568
or 488; 1:1000; Molecular Probes) were used.
Cell Count
GFAP density was measured in a 200-m2 grid at the
lesion site (up to 400 m distal from the center line of the
lesion) using ImageJ software version 1.43u (NIH, Be-
thesda, MD). The GFAP density was averaged from 5
boxes per section and 10 sections per spinal cord, with
the results being presented as the percentage of total
area. To avoid bias choice of fields, the fields that were
taken were 200 m apart in any direction.
Cell proliferation was quantified by counting Ki-67–
positive cells in a 200-m2 grid at the lesion site (400
m distal from the center line of the lesion). For neuronal
counts, NeuN-positive cells were counted at two different
distances from the lesion site (300 m and 5 mm proxi-
mal to the lesion site) in a 200-m2 field. Traced neurons
were counted at four different distances from the lesion
site (as specified in the graph). Synaptophysin density
was measured around traced neurons at the lesion site
using ImageJ software.
Microscopy
Sections were examined by bright field or fluorescence
microscopy using an Axioplan Z1 epifluorescence micro-
scope (Carl Zeiss MicroImaging GmbH). Photomicro-
graphs (1300  1030 dpi) were obtained with 2.5 and
5 Plan-Neofluar objectives (Carl Zeiss MicroImaging
GmbH) and were acquired as digital images using an
AxioCam digital camera connected to AxioVision soft-
ware version 4.4 (Carl Zeiss MicroImaging GmbH). Im-
ages were cropped and sized using Adobe Photoshop
11 and Illustrator 14 (Adobe Systems Inc., San Jose, CA).
To confirm colocalization, optical sections of the sample
were acquired using an Axoioplan Z1 microscope
Neuroprotection of Anti-LPA After SCI 983
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using AxioVision software.
Analysis of Signal Transduction
To examine signaling pathways (intact spinal cord, spinal
cord after SCI with or without mAb treatment; the inves-
tigator was blinded to the nature of the drugs delivered),
the spinal cord tissue–included lesion site 3 mm from
each side was lysed 7 days after SCI with lysis buffer [50
mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10% glycerol,
1% Triton X-100, 1 mmol/L EDTA, 1 mmol/L EGTA (pH 8),
1.5 mmol/L MgCl2, 2 mmol/L phenylmethylsulfonyl fluo-
ride, 0.2 mmol/L Na3VO4] and a protein inhibitor cocktail
(Roche Diagnostics). The lysates were then clarified by
centrifugation, and protein levels were detected using
Bradford assay (Bio-Rad Laboratories, Hercules, CA).
For Western blot analysis, protein samples were mixed
with one-quarter volume of 4 loading buffer (200
mmol/L Tris-HCl, pH 6.8, 8% SDS, 0.04% bromophenol
blue, 40% glycerol, 400 mmol/L dithiothreitol) and heated
for 5 minutes at 100°C. Proteins (30 g per sample) were
resolved by SDS-PAGE using 8% to 16% gradient poly-
acrylamide gels (Gradipore, Frenchs Forest, Australia) in
running buffer (25 mmol/L Tris, 200 mmol/L glycine, 0.1%
SDS) and were electrophoretically transferred onto a ni-
trocellulose membrane (0.45 m; Bio-Rad Laboratories)
in transfer buffer (25 mmol/L Tris, 192 mmol/L glycine,
20% methanol). Membranes were blocked for 2 hours in
Tris-buffered saline (0.05 mol/L Tris, pH 7.5, 0.15 mol/L
NaCl, 0.1% Tween 20) containing 6% skimmed milk pow-
der and incubated with rabbit anti–p-MAPK (1:1000; Cell
Signaling Technology Inc.) overnight, followed by a sec-
ondary antibody linked to horseradish peroxidase (HRP–
anti-rabbit IgG, 1:1000; Cell Signaling Technology Inc.).
Immunoreactive bands were detected using an en-
hanced chemiluminescence reagent (Pierce Biotechnol-
ogy, Rockford, IL). Membranes were stripped using gly-
cine solution (0.2 mol/L; pH 2) at 60°C for 10 minutes,
followed by three washes in Tris-buffered saline with
Tween and incubation with rabbit anti-MAPK (1:1000;
Cell Signaling Technology Inc.). Alternatively, samples
were loaded onto two different gels with the same protein
amount, and each membrane was incubated with anti–
p-MAPK or anti-MAPK Ab.
Rho GTPase activation was detected by using the rho-
tekin Rho-binding domain assay according to the manu-
facturer’s instruction (Upstate Biotechnology, Lake
Placid, NY) on spinal cord tissue lysates as described
previously (350 g per sample). Endogenous Rho-GTP
was precipitated from the tissue lysates at 4°C for 1 hour
using 30 g of the rhotekin Rho-binding domain agarose
for each sample. The beads were pelleted by centrifuga-
tion at 14,000  g for 2 minutes, washed three times with
the lysis buffer, and resuspended in 4 loading buffer.
The eluted protein samples were resolved on 12% SDS
gels and were analyzed by Western blot analysis. Rho
was detected using rabbit anti-Rho (1:1000; Cell Signal-
ing Technology Inc.).
Quantitative analysis of detected bands was per-
formed by densitometric analysis of scanned blots usingImageJ software. Statistical comparison was made
against adjusted relative densities of triplicate loaded
samples using GraphPad Prism software.
Behavioral Analyses
The investigator was blinded to the nature of the treat-
ments. Ability to walk on a horizontal was performed as
previously described.37,39 The ability to walk on a hori-
zontal wire grid (1.2  1.2-cm grid spaces; 35  45-cm
total area) was determined to assess their ability to con-
trol movement in the left hind limb. The mice were tested
1 to 5 weeks after SCI, once a week. Each mouse was
allowed to walk freely around the grid for 2 minutes be-
fore testing and then was tested for 3 minutes. When the
left hind limb paw protruded entirely through the grid,
with all the toes and the heel extending below the wire
surface, this was counted as a misstep. The total number
of steps taken with the left hind limb was also counted.
The results are expressed as the percentage of accurate
footsteps.
Open-field locomotion score was evaluated by using
the modified Basso-Beattie-Bresnahan (mBBB) scoring
system of 20 points.40 The mice were placed in an open
field on a nonslippery surface (46  57 cm). In each
testing session, the mice were observed individually for 3
minutes by the observer. The mice were tested once per
week every week for 5 weeks. Decoding of the samples
was performed only after the data were quantified and
analyzed.
In the data presented herein, one animal in the cohort
“B3” died and 2 “B3” animals and 2 “isotype-treated
control” animals were removed because of double pa-
ralysis.
Statistical Analysis
All the sets of experiments were performed at least three
times in triplicates (n refers to the number of independent
experiments performed on different cell cultures/ani-
mals). All the data are expressed as mean  SEM as
indicated. Significance of the differences was evalu-
ated using either two-tailed t-tests with 95% confi-
dence intervals in case of only two variables to com-
pare or the one-way analysis of variance followed by
the Tukey test for multiple comparisons, with  
0.001. Statistical significance was established at P 
0.05, P  0.01, and P  0.001. For behavioral analysis,
fish locomotor analysis, mBBB score, and grid walking, a
nonparametric Mann-Whitney test was used, with  set to
5% (P  0.05 and P  0.01).
Results
LPA Mediates Inflammatory Responses and
Glial Cell Proliferation After SCI in the Zebrafish
Danio rerio
Contrary to what is observed in mammals, fish regenerate
their spinal cord after full transection within a few weeks
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ronal regeneration.26,27,32 Accordingly, we examined the
effect of local LPA administration after full spinal cord
transection in the zebrafish to determine the different
cellular responses in vivo to LPA at the lesion site. Taking
advantage of various zebrafish Tg lines, we tracked key
cellular responses to injury and to LPA administration.
Leukocytes, glia, and neurons were analyzed in Tg fish
expressing the GFP transgene under the control of the
macrophage lineage promoter macrophage expressed
gene1 Tg(mpeg1:GFP), the neutrophil lineage promoter
myelopeoxidase Tg(mpx:GFP)i114,3,28,29 the GFAP pro-
moter Tg(GFAP:GFP)mi2001,30 or the motor neuron Islet1
promoter Tg(isl1:GFP)2rw012.31 RT-PCR of the adult fish
brain and spinal cord revealed that LPA1 is highly ex-
pressed in the adult fish CNS (Figure 1A). Based on
morphologic features and location, in situ hybridization
showed that LPA1 is expressed on large neuronal-like
cells along the spinal cord and glia-like cells located
along the midline and central canal of the spinal cord
(Figure 1, B and C). We next tested the responses to
injured animals after LPA treatment (see Materials and
Methods). Six hours after SCI, LPA-treated animals dis-played substantially more apoptotic cells, assessed by
TUNEL staining at the lesion site, and more neutrophils
(Figure 1, D–F). Three days after complete spinal cord
transection, macrophage infiltration was observed at the
lesion site, and some macrophage/microglia activation
was also observed distal from the lesion site (Figure 1G).
Significantly more cells expressing the macrophage/mi-
croglia marker mpeg1 were activated in the injured spinal
cords of LPA-treated zebrafish, although at the lesion
site, a substantial increase in macrophage infiltration was
not seen (Figure 1, G–M). These results suggest that LPA
promotes inflammation and neuronal cell death during
the acute phase of neurotrauma.
The longer-term, secondary effects of LPA were then
studied in animals subjected to SCI. Five days after SCI,
LPA administration increased glial cell proliferation at the
central canal (Figure 2A, B, and E), and these cells also
demonstrated increased levels of GFAP expression com-
pared with injection of vehicle alone (Figure 2, C and D),
suggesting that LPA promotes glial cell proliferation and
reactivity in the late, secondary phases of neurotrauma.
In addition, 10 days after SCI, islet1-expressing neurites
Figure 1. LPA promotes inflammation and cell
death in zebrafish after SCI. A: LPA1 expressed in
the brain and spinal cord of adult zebrafish. B,
brain; L, liver; M, muscle; SC, spinal cord; NC,
negative control consisting of no cDNA in the
PCR. B and C: In intact adult zebrafish spinal
cord, in situ hybridization shows LPA1 expres-
sion in large neuronal cells along the spinal cord
(arrowheads) and in glial cells along the mid-
line in spinal cord tissue (arrows). Six hours
after SCI in the mpx:GFP line, there is little infil-
tration of neutrophils into the control fish and
some TUNEL-labeled cells (D); however, in LPA-
treated animals, increased neutrophil infiltration
and neuronal apoptosis was demonstrated by
TUNEL staining (E). F: Quantitation of neutro-
phils at the lesion site reveals a significant in-
crease in LPA treatment versus control (Con).
Results are given as mean  SEM (n  5 in each
group). *P  0.001 by two-tailed t-test, 95% con-
fidence. G: Three days after SCI in the mpeg1:
GFP line demonstrating infiltration of mpeg1-
expressing cells in the lesion site (box
enlargement; H) and their presence distal from
the lesion site (box enlargement; I). J: LPA treat-
ment increased the presence of mpeg1-express-
ing cells distal to the lesion site (box enlarge-
ment; K), with similar macrophage infiltration
(box enlargement; L). M: Quantitation of mac-
rophages/microglia shows a significant increase
in LPA-treated versus control (Con) spinal cords.
Results are mean  SEM (n  8 in each group)
*P  0.001 by two-tailed t-test, 95% confidence.
Scale bars: 50 m (B, C, H, I, K, and L); 100 m
(D and E); 300 m (G and J).were observed sprouting at the lesion site, and quantita-
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lesion site revealed substantially more neurites in control
compared with LPA treatment (Figure 2F). Moreover, 3
weeks after SCI, neurites were observed regenerating
through the lesion site in control animals, which is in
contrast to LPA-treated fish, which displayed reduced
neurite sprouting (Figure 2G). Overall locomotor recovery
of LPA-treated fish was worse, although this did not reach
significance at this time point (Figure 2H). This suggests
that the regeneration process still occurs to some extent
in LPA-treated zebrafish. Collectively, these results sug-
gest that LPA increases inflammation and glial cell pro-
liferation and reduces neurite sprouting in the zebrafish
model of regeneration after SCI.
Since the exogenous LPA application in the zebrafish
model suggested that LPA may have an inhibitory role in
regeneration after neurotrauma, thereby influencing inflam-
matory cell infiltration and activation, glial cell proliferation,
and neuronal sprouting inhibition, we next used the murine
model of SCI to investigate the role of endogenous LPA
generation during neurotrauma and to determine whether
intervention in LPA signaling could be a useful therapeutic
strategy in the treatment of SCI. Consequently, an anti-LPA
mAb was developed as a therapeutic molecular sponge to
neutralize LPA in a murine model of SCI. The specificity of
the mAb against LPA was initially demonstrated.
Blockage of LPA’s Effect by the Specific
Anti-LPA mAb
The availability of highly specific mAbs directed against LPA
offers a unique tool to probe the role of LPA in cell signaling
and to demonstrate use of the antibody as a potential thera-
peutic. Anti-LPA mAbs specifically bind LPA and prevent theligand from interactingwith its complement of receptors. Table
1 shows a competition ELISA where the murine anti-LPAmAb
B3 was tested for its ability to recognize 18:2 LPA by compar-
ison with a variety of other bioactive lipids delivered at the high
concentration of 2.5 mol/L. The table shows that at this con-
centration of 18:2 LPA as the competing lipid, the binding of
B3 to the plate was inhibited by 71%. In contrast, structurally
related bioactive lipids, such as sphingosine-1-phosphate,
platelet activating factor, and sphingosine, were not recog-
nized by the B3 mAb. In addition, lysophosphatidyl choline,
the immediate precursor of LPA generation by autotaxin, was
not recognized by the B3 mAb, along with other potential
precursors, such as phosphatidic acid or glycerol-3-phos-
phate. Structural phospholipids also did not cross-react, and
neither did the autotaxin inhibitors cyclic LPA and bromometh-
ylene phosphonate–LPA.
Having demonstrated that the B3 mAb was specific for
LPA, it was then studied for its ability to block specific
LPA receptor signaling. For these experiments, the
CHO-K1 EDG2 (LPA1)–, CHO-K1 EDG4 (LPA2)–, and
CHO-K1 EDG7 (LPA3)–-arrestin clones (PathHunter)
generated by DiscoveRx were used in very sensitive as-
says where the readout was a luminescence signal as-
sociated with G-protein–coupled receptors. Figure 3, A,
C, and E, shows the dose-dependent effect of 18:2 LPA
to activate the LPA1/EDG2-, LPA2/EDG4-, or LPA3/EDG7-
overexpressing cells with EC50 values of 82, 293, and
837 nmol/L LPA, respectively. For all three receptors,
Figure 3, B, D, and F, demonstrates the dose-dependent
ability of B3 to completely knock down LPA signaling to
baseline levels of luminescence. Using data from cells
expressing the highest-affinity receptor, LPA1/EDG2 (Fig-
ure 3, A and D), the EC50 of LPA required to activate the
Figure 2. LPA increases glia proliferation and
decreases neurite sprouting in zebrafish after
SCI. Five days after SCI in the GFAP:GFP line,
BrdU-positive glial cells proliferate at the central
canal and accumulate at the edges of the lesion
site (A) compared with LPA-treated fish (B).
GFAP expression at the edges of lesion in con-
trol fish (C) compared with more abundant
GFAP expression in LPA-treated animals (D). E:
Quantitation of BrdU-positive cells reveals an
increase with LPA treatment. Results are given as
mean SEM (n 10 in each group). *P 0.001
by two-tailed t-test, 95% confidence). F: Three
weeks after SCI, the Islet1:GFP line shows a
significant decrease in neurite number at the
lesion site in LPA-treated fish compared with
controls (Con). Results are given as mean SEM
(n  8 for each genotype). ***P  0.001 by
two-tailed t-test, 95% confidence). G: Neurite
sprouting in the islet1:EGFP line around the lesion
site in control treatment compared with reduced
neurite number from both sides of the lesion site in
LPA treatment. H: Locomotor recovery assays
show motor function 3 weeks after SCI (n  7
animals from each group) NS, not significant. Scale
bars: 100 m (A, B, and G); 50 m (C and D).receptor was 82 nmol/L, whereas B3 blocked LPA sig-
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antibody concentration of 30 nmol/L, which is stoichio-
metrically sufficient to neutralize the LPA (200 nmol/L)
present in the assay (ie, twice the EC50 for LPA). Sim-
ilar results were observed when B3 was tested for its
ability to neutralize LPA in cells expressing the less
sensitive LPA receptors, LPA2/EDG4 and LPA3/EDG7
Figure 3. Anti-LPA mAb (B3) blocks LPA signaling in LPA1, 2, or 3 overex-
pressing CHO-K1 cells and in human NS/PCs. LPA activates signaling via LPA
receptors LPA1 (A), LPA2 (C), or LPA3 (E). CHO-K1 cells were plated at 2.0 
104 cells per well and were incubated at 37°C/5% CO2. After 24 hours, plates
were starved with reduced serum media at 37°C for another 24 hours. The
LPA standard curve was prepared by titrating 18:2 LPA (0 to 10 mol/L) in
media containing 1 mg/mL of BSA onto the plate and was analyzed as
described in Materials and Methods. B, D, and F: B3 blocks LPA signaling by
inhibiting LPA binding to it receptors. Media containing 200 nmol/L (for
LPA1/EDG2) or 400 nmol/L (for LPA2/EDG4 and LPA3/EDG7) 18:2 LPA and
increasing concentrations of B3 antibody (0 to 2000 g/mL) were added to
the corresponding CHO-K1 cells (B, D, and F, respectively) and processed as
described for the LPA signaling experiment. RLU, relative light unit. Fre-
quency of neurosphere formation (G) and neuronal differentiation (neuron-
forming neurospheres) (H) in the presence or absence (control) of LPA (10
mol/L) and/or B3 (1 mg/mL). Data are expressed as the mean  SEM from
at least three independent experiments. ***P  0.001 by one-way analysis of
variance followed by the Tukey test,   0.001.(Figure 3, D and F).Having determined the potency and specificity of B3 to
block LPA binding to LPA1-3 receptors in the DiscoveRx
cells, the ability of B3 to block LPA-induced biological
effects was then assessed in vitro using human embry-
onic stem cell–derived NS/PCs. These cells were chosen
as a more biologically relevant cell assay readout of the
anti-LPA mAb potency, as we previously reported that
LPA dose dependently inhibits the neural differentiation
of human embryonic stem cell–derived NS/PCs by hav-
ing effects on neurosphere formation and neuronal differ-
entiation.41 We also previously reported that these cells
express LPA1-5 mRNAs.
41 We tested the potency of B3 to
block LPA’s effects in two different cell assays: inhibition
of neurosphere formation and inhibition of NS/PC differ-
entiation toward neurons. As shown in Figure 3, G and H,
the sole application of B3 did not significantly modify
neurosphere formation frequency or neuronal differentia-
tion. As expected, exogenous LPA addition substantially
and significantly inhibited neurosphere formation. Coin-
cubation of LPA with B3 abolished LPA’s effect on neu-
ronal differentiation and neurosphere formation. Alto-
gether, these cell-based assays demonstrate the strong
potency of B3 to block LPA’s biological effects in cells,
including human NS/PCs.
Anti-LPA mAbs Decrease Astrogliosis and
Microglial Activation in the in Vivo Mouse
Model of SCI
Having demonstrated the potency of the murine anti-LPA
mAb B3 to block the effects of LPA in cell assays, the ability
of B3 to block LPA effects in vivowas then tested in amouse
model of SCI. These in vivo studies consisted of treating
hemisectioned animals s.c. twice a week for 1 to 2 weeks
with either isotype control or B3 (0.5 mg per mouse, 25
mg/kg, in a blinded manner) after SCI. At both time points,
a reduction in astrocyte reactivity was observed after anti-
LPA mAb treatment. Densitometry revealed a significant
decrease in GFAP expression by astrocytes around the
lesion site in B3-treated mice compared with isotype-
treated control mice 1 week (Figure 4, A, B, D, E, and G)
and 2 weeks (data not shown) after injury. In addition, this
reduced glial response resulted in a marked reduction in
glial scarring as assessed by immunostaining for chondroi-
tin sulfate proteoglycan, a key component of the glial scar
(Figure 4, C and F). These results also demonstrated a
significant reduction in cell proliferation at the lesion site, as
assessed by quantification of the proliferation marker Ki-67
(Figure 4H). Most of the cells were colabeled with GFAP,
suggesting that most of the proliferating cells at the lesion
site at this time point were astrocytes (Figure 4H). These
results suggest that treatment with B3 reduces the astro-
cytic response after SCI and attenuates reactive gliosis.
To understand more precisely the signaling pathways
involved in the LPA effect after SCI, we assessed levels of
the extracellular signal-regulated kinase 1 and 2 phosphor-
ylation (p-MAPK) in the spinal cord of sham or hemisec-
tioned animals that received either B3 treatment or its iso-
type control for 1 week (Figure 4, I, and J). Western blot
analysis indicated high and sustained levels of extracellular
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spinal cords compared with sham spinal cords (Figure 4J).
Moreover, treatment with the anti-LPA mAb strongly re-
duced p-MAPK down to control levels, suggesting that en-
dogenous LPA induces extracellular signal-regulated ki-
nase 1 and 2 phosphorylation after SCI (Figure 4J). These
data were confirmed by immunostaining of the spinal cords,
which indicated colocalization of p-MAPK and GFAP, dem-
onstrating that LPA-dependent extracellular signal-regu-
lated kinase 1 and 2 signaling in the tissue likely resulted
from astrocyte activity (Figure 4I). In addition, B3 treatment
also decreased Rho activation (Figure 4K), a major regula-
tor of cytoskeletal changes.42 Activation of Rho in reactive
astrocytes and in neuronal growth cone collapse has beenreported after SCI.37,43,44 Furthermore, CD11b immuno-
staining and density quantitation also revealed that B3 sig-
nificantly reduced microglial cell activation near the lesion
site compared with isotype-treated control (Figure 5), which
may suggest that LPA contributes to the proinflammatory
response at the lesion site.
Anti-LPA mAb Is Neuroprotective and
Decreases Neuronal Apoptosis Near the
Lesion Site After SCI in the Mouse
In the mouse 1 week after SCI, treatment with B3 dramat-
Figure 4. Anti-LPA mAb (B3) reduces glial scar
after SCI. Immunostaining at the injury site of
mouse spinal cords 1 week after SCI shows a
dense network of astrocytes expressing high lev-
els of GFAP (A and B), which is reduced after B3
treatment (D and E). C: Immunostaining for
chondroitin sulfate proteoglycans 2 weeks after
lesioning revealed that the scar was diminished
in B3-treated mice (F). G: Quantitation of GFAP
density around the lesion site showed a signifi-
cant decrease with B3 treatment. Results are the
mean  SEM percentage of GFAP staining den-
sity in the field (n 7 in each group). *P 0.001
by two-tailed t-test, 95% confidence). Most pro-
liferating cells at the lesion site are GFAP posi-
tive. H: Quantitation of Ki-67–positive cells at
the lesion site showed a significant decrease
with B3 treatment. Results are the mean  SEM
number of Ki-67–positive cells in the field (n 
7 in each group). *P  0.001 by two-tailed t-test,
95% confidence). I: p-MAPK levels were re-
duced on astrocytes at the lesion site in B3-
treated mice. Western blot analysis of spinal
cord tissue 1 week after injury showed a signif-
icant reduction in p-MAPK signaling (n  7) (J)
and Rho-GTP levels (n  4) (K) in B3-treated
mice. Data are expressed as the mean  SEM
from at least three independent animals. *P 
0.05, **P  0.01 by one-way analysis of variance
followed by the Tukey test,   0.001. Scale
bars: 200 m (A, C, D, and F); 50 m (B, E, H,
and I).ically reduced apoptosis at the lesion site, as revealed by
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colocalized with NeuN in isotype-treated controls (Figure
6, E–G), suggesting that B3 had an antiapoptotic effect
on neurons by virtue of neutralizing the proapoptotic LPA
produced at the injury site. This observation is further
supported by decreased activation of caspase-3 at the
lesion site in B3-treated animals compared with isotype-
treated control mice (Figure 6, H and I); furthermore,
caspase-3 colocalized with NeuN (Figure 6, J–L). More-
over, these data indicate a statistically higher number of
NeuN-positive cells at the lesion site in B3-treated ani-
mals compared with isotype-treated controls (Figure 6M),
suggesting increased neuronal survival of 51%, from a
mean SEM of 7.68% 2.2% to 11.6% 2.2% cells per
field (Figure 6M). Thus, these data demonstrate that B3 is
neuroprotective after SCI.
Anti-LPA mAbs Promote Recovery After SCI in
the Mouse
As B3 decreased astrogliosis and neuronal cell death 1
to 2 weeks after SCI, we next examined whether this
treatment would promote a favorable environment for
Figure 5. Anti-LPA mAb (B3) reduces microglia activation around the lesion
site. One week after SCI, CD11b immunostaining in isotype-treated control
mice (A, and C) compared with reduced levels in B3-treated mice (B and D).
E: Quantitative analysis of the reactive microglia marker CD11b from 200-
mm2 areas adjacent to the lesion site. Results are the mean  SEM (n  7 in
each group). *P 0.001 by two-tailed t-test, 95% confidence). Scale bar s: 100
m (A and B); 50 m (C and D).neurons to regenerate. Eight weeks after injury, axonalregeneration through the lesion site was not observed in
any isotype mAb–treated control animals but was ob-
served only in a few animals treated with B3 for 2 weeks,
hence suggesting that B3’s effect is not mainly through
regeneration (data not shown). We observed a signifi-
cantly higher number of tetramethylrhodamine dextran–
traced neurons 500 m to 1 mm proximal to the lesion
site in all B3-treated mice compared with isotype-treated
control animals (Figure 7, A–C). Moreover, these were
accompanied by a significant increase in synapse den-
sity in the area around traced neurons, as determined by
synaptophysin immunostaining (Figure 7, D–F).
As a critical consequence of the neuroprotective and
proregenerative effects of the anti-LPA mAb in vivo, in-
jured mice were assessed for functional recovery after a
2-week antibody treatment, as determined by use of the
left hind limb in the grid walking assay and the mBBB
scale. As seen in Figure 8A, anti-LPA B3 treatment re-
sulted in a significant improvement in the ability to walk
on a grid 3 weeks after SCI. SCI mice receiving B3
treatment made far fewer foot falls and showed greater
weight support with the affected left hind limb (Figure
8A). B3-treated mice also showed significant improve-
ments in function by 4 weeks after SCI, as assessed by
the modified open-field behavior test using the mBBB
scale (Figure 8B).40 These data demonstrate the rele-
vance of anti-LPA mAb treatment for improving key be-
havioral outcomes after neurotrauma.
Discussion
Herein we demonstrate for the first time the role of LPA in
promoting neuronal cell death and reactive gliosis and
inhibiting neuronal regeneration after SCI using murine
and zebrafish models of SCI. We also demonstrate the
neuroprotective and proregenerative effects of a thera-
peutic anti-LPA antibody and the ability of antibody ther-
apy to improve functional and behavioral outcomes.
Using the zebrafish model of regeneration after neu-
rotrauma and taking advantage of several Tg zebrafish
lines expressing markers for key cellular components of
neurotrauma, we demonstrated the ability of LPA to in-
hibit the normal regenerative response after SCI. In par-
ticular, LPA mediates neuronal death, microglial activa-
tion, astroglial proliferation, and GFAP up-regulation and,
over the long term, inhibits neurite sprouting in injured
zebrafish.
Using the murine SCI model, these data using a spe-
cific anti-LPA mAb strongly indicate that LPA produced
endogenously after neurotrauma inhibits SCI regenera-
tion by increasing gliosis and promoting neuronal death.
The specific mAb raised against LPA, B3, inhibited the
effects of LPA in vitro and in vivo. The anti-LPA mAb not
only validates the role of LPA in neurotrauma but also
suggests that LPA is causally involved in nearly all the
pathologic consequences of SCI, including gliosis, nerve
cell death, inflammatory responses, and the inhibition of
neuroregeneration. However, it remains to be determined
whether these consequences are due to pleiotropic ef-
fects of LPA or to a sole cellular effect leading to broader
two-tail
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mAb significantly reduced glial scar formation and in-
flammatory responses while substantially increasing neu-
ronal survival. The observed increasing density of syn-
apses around neuronal cells proximal to the lesion site
after mAb treatment may suggest that neuronal activity
was also improved compared with isotype-treated control
mice. All these lead to motor function improvement with
mAb treatment. All the mice exhibited increased neuronal
cell survival and increased synaptic density at the rostral
part of the lesion site, suggesting that the antibody pro-
moted neuronal survival rather than regeneration. After
spinal hemisection, a gradual return of locomotor function
occurs in mice45,46 and is thought to be due to activation
of central pattern generators.47 Due to the neuronal pro-
survival effects of anti-LPA mAb treatment, neurons in-
nervating the hip (found in the region of the hemisection)
improve significantly beyond normal recovery. The sur-
vival effect of the antibody on neurons explains the im-
provement of B3 treatment on locomotor hip movement
and weight support as measured by the behavioral read-
outs used in this study and, ultimately, improves locomo-
tor function.
These data in zebrafish and mice support the concept
Figure 6. Anti-LPA mAb (B3) is neuroprotective by reducing apoptotic neur
site in isotype-treated control mice (A and B; box enlargement) compared
Colabeling of TUNEL staining with the neuronal marker NeuN shows apopto
(H) compared with B3 (I) treatment and colocalized with NeuN (J–L).M: Qua
of the lesion site) reveals that in B3 treatment, the number of neuronal cells
SEM of NeuN-positive cells in the field (n  7 in each group). *P  0.001 by
and J–L).that LPA promotes activation of microglial cells, which, inturn, might also regulate LPA de novo synthesis.1 It has
been demonstrated previously in the adult mouse spinal
cord that LPA is synthesized by microglial cells in their
early phase of activation and that this LPA is likely re-
sponsible for neuropathic pain.48 Consistent with this re-
port, we demonstrate that anti-LPA mAb treatment signif-
icantly reduced microglial activation after SCI. Although
outside the scope of the present study, one could spec-
ulate that the anti-LPA mAb blocks de novo synthesis of
LPA by microglia, hence reducing their activation by dis-
rupting the autocrine and paracrine actions of LPA on
microglia.
These data also suggest that the anti-LPA mAb treat-
ment–induced improvements are likely to be mediated by
the decrease in Rho-GTP and p-MAPK activation path-
ways that mediate glial cell proliferation and differentia-
tion, resulting in scarring. In addition, the Rho pathway
has already been described as the main pathway used
by LPA to induce growth cone collapse1 and is inhibited
partially by antibody treatment.
The present study with the anti-LPA mAb provides in
vivo support of previous work suggesting that LPA plays
an active role in blocking the regenerative response by
inhibiting the neuronal differentiation of NS/PCs1,49 as
th after SCI. One week after SCI, apoptotic cells were observed at the lesion
duced TUNEL staining in B3 treatment (C and D; box enlargement). E–G:
ns (arrowheads). Immunostaining for active caspase-3 increased in control
n of number of neuronal cells at the lesion site and 5 mm proximal (upstream
lesion site was significantly higher than in controls. Results are the mean 
ed t-test, 95% confidence). Scale bars: 100 m (A, B, H, and I); 50 m (C–Gonal dea
with re
tic neuro
ntitatio
at theantibody treatment promoted axonal sprouting after neu-
990 Goldshmit et al
AJP September 2012, Vol. 181, No. 3rotrauma in SCI mice. Consistent with the in vivo effects of
the antibody, the in vitro data obtained on human embry-
onic stem cell–derived NS/PCs demonstrated the ability
of the anti-LPA mAb to counter negative effects of LPA on
NS/PCs. Thus, the present data also indicate a potential
role of LPA mAbs to modify the outcome of neurogenesis
after inflammation or injury by reducing inhibition of
NS/PC neuronal differentiation by LPA.
We demonstrate for the first time that blocking LPA
signaling may be a useful and novel therapeutic strategy
for SCI. Targeting the ligand with the anti-LPA mAbs may
offer some advantages as a therapeutic strategy in the
treatment of neurotrauma.1 Lpath Inc. has now human-
ized B3 and performed affinity maturation for eventual
use in clinical trials. The murine mAb was used in the
mouse model for proof of concept and to avoid compli-
cating results due to potential immunogenicity and in-
Figure 7. Anti-LPA mAb (B3) increases neuronal survival and synaptic den-
sities at the lesion site. A–C: Eight weeks after SCI, in B3-treated mice,
significantly more traced neurons (arrowheads) are observed in the areas
adjacent and proximal to the lesion site (n  7) compared with controls
(n  8). D–F: Quantitation of synaptic density around the traced neuronal
cells shows significantly more synapses in B3-treated mice compared with
isotype-treated control mice. TMRD, tetramethylrhodamine dextran. Results
are mean  SEM cell number or density in the field. *P  0.001 by two-tailed
t-test, 95% confidence. Scale bars: 100 m (B and C); 25 m (E and F).flammatory effects of using a human antibody in a mouse.It must be appreciated that this was a proof-of-concept
study intended to demonstrate a role of LPA in SCI and
needs to be followed up with other studies where the
dosing regimen is fully explored as per the dose level and
therapeutic window. Regarding the therapeutic window,
we would not move forward in preclinical development in
investigational new drug (IND)-enabling studies unless
we can demonstrate that our antibodies can be effica-
cious when given in a therapeutically relevant timeframe
after injury, as well as a relevant route of administration
(i.v. versus s.c. or even i.t.). Moreover, once the dose
level and therapeutic window are optimized, we will test
the humanized mAbs to make sure that a dosing regimen
is not complicated by a mouse-against-human antibody
immunogenicity or by inflammatory responses. Although
this was a proof-of-concept study, one can argue that the
exposure of the animal to mAb portends efficacy in a
clinically relevant timeframe, as the pharmacodynamics
of our mAb in mice demonstrates that maximum expo-
sure in blood after s.c. injection does not occur until 24
hours after the first s.c. injection. Thus, the therapeutic
benefit seen in this study extends well into what could be
a clinically relevant timeframe.
A related limitation of this study is the observation that
the extent of neuroprotection seems to fall off beyond 1
mm from the injury site. One would expect that optimizing
the therapeutic regimen in future planned studies will
extend this anatomical limitation. Regardless of the ana-
tomical limitation, substantial and significant improve-
ments in functional behavior were observed.
Taken together, the present work suggests that anti-
LPA mAbs could be a useful approach in treating SCI
and may have advantages over other approaches in-
tended to intervene in the LPA signaling pathway. Tar-
geting the enzymes of the LPA synthetic pathways with
enzyme inhibitors or LPA analogs presents significant
challenges considering that the metabolic pathway of
LPA is complex and that multiple parallel pathways for
LPA synthesis exist.50 Similarly, the receptor-specific an-
tagonist approach presents pitfalls as most cell types
express more than one LPA receptor subtype and the
pattern of receptor expression can change during the
progression of disease. Because LPA receptors share
signaling pathways, the activities of these receptors
Figure 8. Anti-LPA mAb (B3) improves motor function after SCI. A:Walking
on a grid was significantly improved after 2 weeks of treatment with B3.
Results are given as mean SEM. *P 0.05 by nonparametric Mann-Whitney
test,   5%). B: The mBBB score was measured up to 5 weeks after SCI in
isotype-treated control (n 8) and B3-treated (n 7) mice. Results are given
as mean  SEM. **P  0.01 by nonparametric Mann-Whitney test,   5%).
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AJP September 2012, Vol. 181, No. 3might be redundant, and blockage of one receptor may
be insufficient to fully silence the pathway. Similarly,
blocking even a principal pathway for LPA synthesis,
such as targeting autotaxin, would not totally eliminate
extracellular LPA levels as other routes of LPA synthesis
exist. In light of these considerations, the neutralization of
the ligand itself may be a simple and effective approach
for the development of an LPA-based therapeutic.
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